Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR – Get Free Report) traded down 12.1% during trading on Monday . The stock traded as low as $14.53 and last traded at $14.70. 115,379 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 128,262 shares. The stock had previously closed at $16.73.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen downgraded Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Get Our Latest Analysis on ZSQR
Coeptis Therapeutics Stock Down 9.0%
Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.
Institutional Trading of Coeptis Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP purchased a new stake in Coeptis Therapeutics during the third quarter worth approximately $140,000. Marshall Wace LLP acquired a new stake in shares of Coeptis Therapeutics in the fourth quarter worth $259,000. State Street Corp increased its position in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares in the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
Featured Articles
- Five stocks we like better than Coeptis Therapeutics
- Marathon Petroleum Is Back, But Cycles Still Matter
- The SpaceX Sell-Off May Be More Than a Market Overreaction
- Chevron’s Microsoft Deal Turns Natural Gas Into an AI Trade
- Why nVent Could Be a Long-Term AI Infrastructure Winner
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
